Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC grew its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 85.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 650,000 shares of the company's stock after purchasing an additional 300,000 shares during the period. Jasper Therapeutics comprises approximately 1.2% of Integral Health Asset Management LLC's investment portfolio, making the stock its 29th largest holding. Integral Health Asset Management LLC owned 4.33% of Jasper Therapeutics worth $13,897,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of JSPR. Wells Fargo & Company MN boosted its position in Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Jasper Therapeutics in the fourth quarter valued at approximately $223,000. Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics in the third quarter valued at approximately $251,000. Barclays PLC increased its position in shares of Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company's stock valued at $304,000 after buying an additional 12,308 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Jasper Therapeutics by 239.8% in the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after buying an additional 11,567 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JSPR. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Oppenheimer cut their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a research report on Thursday. Finally, UBS Group cut their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research report on Tuesday. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics currently has a consensus rating of "Buy" and an average target price of $62.22.

Jasper Therapeutics Stock Performance

Shares of JSPR traded up $0.06 during trading hours on Friday, hitting $4.93. 215,340 shares of the stock were exchanged, compared to its average volume of 292,738. Jasper Therapeutics, Inc. has a 12-month low of $3.13 and a 12-month high of $26.84. The company has a market cap of $74.06 million, a price-to-earnings ratio of -1.04 and a beta of 2.74. The stock's 50-day moving average price is $4.60 and its two-hundred day moving average price is $10.93.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24). On average, research analysts expect that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.